A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation

Journal of Clinical Psychiatry

Volumn 69, Issue 12, 2008, Pages 1869-1879

  Satterthwaite, Theodore D ^a   Wolf, Daniel H ^a   Rosenheck, Robert A ^b,c   Gur, Raquel E ^a,d   Caroff, Stanley N ^a,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Vet Aff Connecticut Hlth Care S   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHOLINERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PROMETHAZINE; ZIPRASIDONE;

ACUTE DISEASE; AGITATED DEPRESSION; AKATHISIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; META ANALYSIS; MONOTHERAPY; PARKINSONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CHOLINERGIC ANTAGONISTS; DRUG THERAPY, COMBINATION; FEMALE; HALOPERIDOL; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 60349087399     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n1204     Document Type: Article

References (97)

1. Lindenmayer JP. The pathophysiology of agitation. J Clin Psychiatry 2000;61(suppl 14):5-10
2. Marder SR. A review of agitation in mental illness: treatment guidelines and current therapies. J Clin Psychiatry 2006;67(suppl 10):13-21
3. Rund DA, Ewing JD, Mitzel K, et al. The use of intramuscular benzodiazepines and antipsychotic agents in the treatment of acute agitation or violence in the emergency department. J Emerg Med 2006;31(3):317-324
4. Altamura AC, Sassella F, Santini A, et al. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 2003;63(5):493-512
5. Rosenbaum JF, Arana GW, Hyman SE, et al. Handbook of Psychiatric Drug Therapy. Philadelphia, Pa: Lipincott, Williams, and Wilkins; 2005
6. van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. Br Med J 1999 Sep;319(7210):623-626
7. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161(3):414-425
8. Van Gerpen JA. Drug-induced parkinsonism. Neurologist 2002;8(6):363-370
9. Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001;158(7):1149-1151
10. Brook S, Lucey JV, Gunn KP, for the Ziprasidone IM Study Group. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J Clin Psychiatry 2000;61(12):933-941
11. Brook S, Walden J, Benattia I, et al. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Berl) 2005;178(4):514-523
12. Andrezina R, Marcus RN, Oren DA, et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. Curr Med Res Opin 2006;22(11):2209-2219
13. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002;59(5):441-448
14. Tran-Johnson TK, Sack DA, Marcus RN, et al. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007;68(1):111-119
15. Currier GW, Citrome LL, Zimbroff DL, et al. Intramuscular aripiprazole in the control of agitation. J Psychiatr Pract 2007;13(3):159-169
16. Daniel DG, Zimbroff DL, Swift RH, et al. The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. Int Clin Psychopharmacol 2004;19(1):9-15
17. Andrezina R, Josiassen RC, Marcus RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl) 2006;188(3):281-292
18. Brook S. Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia. J Clin Psychiatry 2003;64(suppl 19):13-18
19. Tulloch KJ, Zed PJ. Intramuscular olanzapine in the management of acute agitation. Ann Pharmacother 2004;38(12):2128-2135
20. Wagstaff AJ, Easton J, Scott LJ. Intramuscular olanzapine: a review of its use in the management of acute agitation. CNS Drugs 2005;19(2):147-164
21. Zimbroff DL, Allen MH, Battaglia J, et al. Best clinical practice with ziprasidone IM: update after 2 years of experience. CNS Spectr 2005;10(9):1-15
22. Mendelowitz AJ. The utility of intramuscular ziprasidone in the management of acute psychotic agitation. Ann Clin Psychiatry 2004;16(3):145-154
23. Arana GW, Goff DC, Baldessarini RJ, et al. Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia. Am J Psychiatry 1988;145(8):993-996
24. Arya DK. Co-prescription of anticholinergic drugs with neuroleptics [letter]. Br J Hosp Med 1992 Feb-Mar;47(4):304
25. Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 1983;40(10):1113-1117
26. Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry 2007;68(12):1876-1885
27. Bagnall A, Lewis RA, Leitner ML. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev 2000;(4):CD001945
28. Belgamwar RB, Fenton M. Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database Syst Rev 2005 Apr;(2):CD003729
29. Allen MH. Managing the agitated psychotic patient: a reappraisal of the evidence. J Clin Psychiatry 2000;61(suppl 14):11-20
30. Allen MH, Currier GW, Carpenter D, et al. The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract 2005 Nov;11(suppl 1):5-108
31. Allen MH, Currier GW, Hughes DH, et al. Treatment of behavioral emergencies: a summary of the expert consensus guidelines. J Psychiatr Pract 2003;9(1):16-38
32. Battaglia J. Pharmacological management of acute agitation. Drugs 2005;65(9):1207-1222
33. Buckley PF, Noffsinger SG, Smith DA, et al. Treatment of the psychotic patient who is violent. Psychiatr Clin North Am 2003;26(1):231-272
34. Lukens TW, Wolf SJ, Edlow JA, et al. Clinical policy: critical issues in the diagnosis and management of the adult psychiatric patient in the emergency department. Ann Emerg Med 2006;47(1):79-99
35. Marco CA, Vaughan J. Emergency management of agitation in schizophrenia. Am J Emerg Med 2005;23(6):767-776
36. McAllister-Williams RH, Ferrier IN. Rapid tranquillisation: time for a reappraisal of options for parenteral therapy. Br J Psychiatry 2002;180:485-489
37. Petit JR. Management of the acutely violent patient. Psychiatr Clin North Am 2005;28(3):701-711
38. Huf G, da Silva Freire Coutinho E, Fagundes HM Jr, et al. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro-Brazil: a prevalence study. BMC Psychiatry 2002;2:4
39. Red Book 2007: Pharmacy's Fundamental Reference. Philadelphia, Pa: Thompson Scientific; 2007
40. Raveendran NS, Tharyan P, Alexander J, et al. Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine. BMJ 2007 Oct;335(7625):865
41. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19
42. Barnes TR. The Barnes Akathisia Rating Scale - revisited. J Psychopharmacol 2003;17(4):365-370
43. Murlow CD, Oxman AD. Cochrane Collaboration Handbook. 4th ed. Oxford, UK: Update Software; 1997
44. Review Manager (RevMan [computer program]. version 4.2.). Copenhagen, Denmark: The Cochrane Collaboration; 2003
45. Alexander J, Tharyan P, Adams C, et al. Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: pragmatic randomised trial of intramuscular lorazepam v haloperidol plus promethazine. Br J Psychiatry 2004 Jul;185:63-69
46. Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002;26(4):494-504
47. Kapur S, Arenovich T, Agid O, et al. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry 2005;162(5):939-946
48. Jones B, Taylor CC, Meehan K. The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. J Clin Psychiatry 2001;62(suppl 2):22-24
49. TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ 2003 Sep;327(7417):708-713
50. Barak Y, Mazeh D, Plopski I, et al. Intramuscular ziprasidone treatment of acute psychotic agitation in elderly patients with schizophrenia. Am J Geriatr Psychiatry 2006;14(7):629-633
51. Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 2001;155(2):128-134
52. Huf G, Coutinho ES, Adams CE. Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol versus intramuscular haloperidol plus promethazine. BMJ 2007 Oct;335(7625):869-876
53. Lesem MD, Zajecka JM, Swift RH, et al. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001;62(1):12-18
54. Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001;21(4):389-397
55. San L, Arranz B, Querejeta I, et al. A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients. Eur Psychiatry 2006;21(8):539-543
56. Centorrino F, Meyers AL, Ahl J, et al. An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/ schizoaffective disorder. Hum Psychopharmacol 2007;22(7):455-462
57. Zimbroff DL, Marcus RN, Manos G, et al. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 2007;27(2):171-176
58. Preval H, Klotz SG, Southard R, et al. Rapid-acting IM ziprasidone in a psychiatric emergency service: a naturalistic study. Gen Hosp Psychiatry 2005;27(2):140-144
59. Damsa C, Adam E, De Gregorio F, et al. Intramuscular olanzapine in patients with borderline personality disorder: an observational study in an emergency room. Gen Hosp Psychiatry 2007;29(1):51-53
60. Pascual JC, Madre M, Soler J, et al. Injectable atypical antipsychotics for agitation in borderline personality disorder. Pharmacopsychiatry 2006;39(3):117-118
61. Fulton JA, Axelband J, Jacoby JL, et al. Intramuscular ziprasidone: an effective agent for sedation of the agitated ED patient. Am J Emerg Med 2006;24(2):254-255
62. Kohen I, Preval H, Southard R, et al. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service. Am J Geriatr Pharmacother 2005;3(4):240-245
63. Miceli JJ, Wilner KD, Swan SK, et al. Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers. J Clin Pharmacol 2005;45(6):620-630
64. Brook S. A pilot study of intramuscular ziprasidone in the short-term treatment of patients with acute exacerbation of schizophrenia. Hum Psychopharmacol 2000;15(7):521-524
65. Bushe CJ, Taylor M, Mathew M. Intramuscular Olanzapine: a UK case series of early cases. Ann Gen Psychiatry 2007 Apr;6:11
66. Greco KE, Tune LE, Brown FW, et al. A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients. J Clin Psychiatry 2005;66(7):928-929
67. Barzman DH, DelBello MP, Forrester JJ, et al. A retrospective chart review of intramuscular ziprasidone for agitation in children and adolescents on psychiatric units: prospective studies are needed. J Child Adolesc Psychopharmacol 2007;17(4):503-509
68. Khan SS, Mican LM. A naturalistic evaluation of intramuscular ziprasidone versus intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents. J Child Adolesc Psychopharmacol 2006;16(6):671-677
69. Staller JA. Intramuscular ziprasidone in youth: a retrospective chart review. J Child Adolesc Psychopharmacol 2004;14(4):590-592
70. Hazaray E, Ehret J, Posey DJ, et al. Intramuscular ziprasidone for acute agitation in adolescents. J Child Adolesc psychopharmacol 2004;14(3):464-470
71. Rosenheck RA. Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator. Psychiatr Serv 2005;56(1):85-92
72. Khanna R, Das A, Damodaran SS. Prospective study of neuroleptic-induced dystonia in mania and schizophrenia. Am J Psychiatry 1992;149(4):511-513
73. Baker LA, Cheng LY, Amara IB. The withdrawal of benztropine mesylate in chronic schizophrenic patients. Br J Psychiatry 1983;143:584-590
74. Addonizio G, Alexopoulos GS. Drug-induced dystonia in young and elderly patients. Am J Psychiatry 1988;145(7):869-871
75. Aguilar EJ, Keshavan MS, Martinez-Quiles MD, et al. Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry 1994;151(12):1819-1821
76. Geyer HL, Bressman SB. The diagnosis of dystonia. Lancet Neurol 2006;5(9):780-790
77. Swett C Jr. Drug-induced dystonia. Am J Psychiatry 1975;132(5):532-534
78. Sunderland T, Tariot PN, Cohen RM, et al. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls: a dose-response study. Arch Gen Psychiatry 1987;44(5):418-426
79. Saraf S, Chandra PS. Tardive dyskinesia and second-generation antipsychotics. Am J Psychiatry 2005;162(2):404-405
80. Sramek JJ, Simpson GM, Morrison RL, et al. Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study. J Clin Psychiatry 1986;47(6):305-309
81. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988;45(1):79-91
82. Olanzapine for injection: new formulation. No advantage in agitated patients. Prescrire Int 2004;13(71):92-93
83. Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? a multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997 Jul;15(4):335-340
84. Gillies D, Beck A, McCloud A, et al. Benzodiazpines alone or in combination with antipsychotic drugs for acute psychosis. Cochrane Database Syst Rev 2005 Oct;(4):CD003079
85. Battaglia J, Houston JP, Ahl J, et al. A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia. Clin Ther 2005;27(10):1612-1618
86. Daniel DG, Currier GW, Zimbroff DL, et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. J Psychiatr Pract 2007; 13(3):170-177
87. Wright P, Meehan K, Birkett M, et al. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clin Ther 2003;25(5):1420-1428
88. Hugenholtz GW, Stolker JJ, Heerdink ER, et al. Short-acting parenteral antipsychotics drive choice for classical versus atypical agents. Eur J Clin Pharmacol 2003;58(11):757-760
89. Volavka J, Czobor P, Nolan K, et al. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopharmacol 2004;24(2):225-228
90. Krakowski MI, Czobor P, Citrome L, et al. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2006;63(6):622-629
91. Miller DD, McEvoy JP, Davis SM, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 2005;80(1):33-43
92. Battaglia J, Lindborg SR, Alaka K, et al. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med 2003;21(3):192-198
93. Canas F. Management of agitation in the acute psychotic patient: efficacy without excessive sedation. Eur Neuropsychopharmacol 2007 Mar;17(suppl 2):S108-S114
94. National Institute of Clinical Excellence. The short-term management of disturbed/violent behaviour in inpatient psychiatric settings and emergency departments. London, England: National Institute of Clinical Excellence; 2005
95. Huf G, Alexander J, Allen MH. Haloperidol plus promethazine for psychosis induced aggression. Cochrane Database Syst Rev 2005 Jan;(1):CD005146
96. Shatzberg AF, Nemeroff CB. Textbook of Psychopharmacology. 3rd ed. Arlington, Va: American Psychiatric Publishing; 2005
97. Starke PR, Weaver J, Chowdhury BA. Boxed warning added to promethazine labeling for pediatric use. N Engl J Med 2005 Jun;352(25):2653